Bristol/Otsuka’s Abilify New Rx Share Exceeds 10%
This article was originally published in The Pink Sheet Daily
Executive Summary
Total scripts for the atypical antipsychotic were 700,000 in the fourth quarter, up more than 10% sequentially. Abilify has received additional sales support from Bristol despite the company’s reduction in the overall size of its detail team.